AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...

BioOrbit CEO Dr Katie King said that pre-clinical studies of the crystals produced in space could start as early as 2026.

Biogen has commenced dosing in the Phase III BRAVE study of omaveloxolone in children of two-< 16 years of age with ...

MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

A report from the CDC across the US has found that ASD rates in children aged between 4-8 years were higher in 2022 than in ...